Amoy Diagnostics Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.
April 01, 2024 at 08:42 am
Share
Amoy Diagnostics Co., Ltd. (SZSE:300685) commences share repurchases on March 29, 2024, under the program mandated by shareholders in the Extraordinary General Meeting held on February 26, 2024. As per the mandate, the company is authorized to repurchase up to CNY 200 million worth of its common stock. The shares will be repurchased at no more than CNY 28 per share.
The purpose of the program is to cancel the shares and reduce the share capital of the company. The company will use its own fund to fund the repurchase. The authorization will be valid for 12 months.
Amoy Diagnostics Co Ltd is a pharmaceutical company engaged in research, development, production and sales of molecular diagnostic products. The Company provides testing reagents and testing services for tumor diagnosis. The Companyâs testing reagent products include ADx-ARMS product line for tumor tissue specimen detection, Super-ARMS product line for liquid biopsy, the NGS product line and the FISH product line. The products are used for the detection of non-small cell lung cancer, colorectal cancer, thyroid cancer, melanoma and other malignant tumors. The Company also provides data software to capture and analyze gene sequencing data. The Company provides testing services through its own medical testing institutions, including lung cancer testing, colorectal cancer testing and breast cancer testing.
Amoy Diagnostics Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.
AMOY DIAGNOSTICS CO., LTD. 
